Table 3.
Multivariable analysis of adherence to tobramycin inhalation powder relative to tobramycin inhalation solution (high vs low/medium utilization)
| Variables included in the model | Odds ratio estimate (95% confidence interval) |
|---|---|
| Index drug, gender, age, Charlson Comorbidity | 1.521 (0.992–2.333) |
| A priori variables + employment status | 1.530 (0.996–2.351) |
| A priori variables + health plan type | 1.448 (0.933–2.248) |
| A priori variables + geographic location | 1.566 (1.016–2.413) |
| A priori variables + co-payment | 1.517 (0.989–2.326) |
| A priori variables + comorbidities | |
| Pancreatic insufficiency | 1.555 (1.012–2.390) |
| Gastroesophageal reflux | 1.549 (1.007–2.383) |
| Chronic sinusitis | 1.449 (0.976–2.301) |
| Malnutrition | 1.530 (0.996–2.350) |
| Osteoporosis | 1.519 (0.990–2.330) |
| Liver and lung transplant and aftercare | 1.535 (1.000–2.356) |
| Anxiety | 1.540 (1.003–2.365) |